DigestRedComo funciona
Red
/
Empresas
Es
No verificado

Estrella Immunopharma, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

19 Comunicados de prensa

Ver todos los comunicados de prensa
03/08/2026
Mercado laboral
Ciencia
Biotecnología
Medicina - Varios
Universidad
Farmacéutica
Salud
Escuela/Educación
Oncología
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
29/07/2026
Mercado laboral
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
24/07/2026
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
05/05/2026
Eventos
Biotecnología
Farmacéutica
Salud
Oncología
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
23/03/2026
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
09/02/2026
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
03/02/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Eventos
Industria
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
06/01/2026
Finanzas
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
05/01/2026
Finanzas
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0
04/12/2025
Industria
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Fuente
Estrella Immunopharma, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0